UK markets close in 3 hours 14 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
64.58-0.34 (-0.52%)
At close: 04:00PM EDT
64.58 0.00 (0.00%)
Pre-market: 08:13AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close64.92
Open65.15
Bid64.55 x 600
Ask64.61 x 600
Day's range64.52 - 65.22
52-week range64.33 - 87.87
Volume6,021,471
Avg. volume7,181,201
Market cap80.457B
Beta (5Y monthly)0.23
PE ratio (TTM)179.39
EPS (TTM)0.36
Earnings date08 Aug 2024
Forward dividend & yield3.08 (4.77%)
Ex-dividend date14 Jun 2024
1y target est81.29
  • Business Wire

    Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

    REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.

  • GuruFocus.com

    Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight

    Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)

  • Business Wire

    Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

    FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma.